1400989-25-4

SC-43 is a derivative of sorafenib, an agonist of Src-homology protein tyrosine phosphatase-1 (SHP-1/PTPN6), which reduces liver fibrosis. SC-43 can reduce p-STAT3 and induce apoptosis, and has antitumor activity.

SC-43 (0-10 μM; 24-72 hours; HuCCT-1, KKU-100, and CGCCA cells) treatment reveals the anti-proliferative effects in cholangiocarcinoma (CCA) cell lines in a dose-dependent manner after treating 24, 48 and 72 hours respectively.  
Its treatment shows increased sub-G1 cells and G2-M arrest, indicating SC-43 induced differential apoptotic effects in these cell lines.  
Its (0-10 μM; 24 hours; HuCCT-1, KKU-100, and CGCCA cells) treatment demonstrates significant increase in cleaved caspase-3 and PARP level.  
Its activates SH2 domain-containing phosphatase 1 (SHP-1) activity, leading to p-STAT3 and downstream cyclin B1 and Cdc2 downregulation. Its augments SHP-1 activity by direct binding to N-SH2 and relief of its autoinhibition.

Cell Cycle Analysis

Cell Line:	HuCCT-1, KKU-100, and CGCCA cells
Concentration:	0 μM, 1 μM, 2.5 μM, 5 μM, 10 μM
Incubation Time:	24 hours
Result:	Showed increased sub-G1 cells and G2-M arrest.

Western Blot Analysis

Cell Line:	HuCCT-1, KKU-100, and CGCCA cells
Concentration:	0 μM, 1 μM, 2.5 μM, 5 μM, 10 μM
Incubation Time:	24 hours
Result:	Demonstrated significant increase in cleaved caspase-3 and PARP level.